NCT07441278

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 177 (estimated)
• Sponsor: NS Pharma, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Conditions

• Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interventions

Type	Name	Description
DRUG	NS-863 Low Dose	NS-863 is an orally administered drug.
DRUG	NS-863 High Dose	NS-863 is an orally administered drug.
OTHER	Placebo	An orally administered NS-863 matching placebo.

Timeline

• Start date: 2026-07-01
• Primary completion: 2028-09-14
• Completion: 2028-12-14
• First posted: 2026-02-27
• Last updated: 2026-02-27

Regulatory

• FDA-regulated drug study